Pre-market movers Oct 29, 2026: LLY, HIVE, DASH
Traders are watching GDP and inflation data after the Fed held rates steady, while Eli Lilly results and deal headlines stir premarket focus.
THURSDAY’S TOP READS
- Investors await GDP and inflation data that could reset expectations after the Fed held rates steady.
- Eli Lilly beat estimates and raised its sales outlook again as Zepbound and Mounjaro demand stayed strong.
Overnight
GDP and inflation data lead after the Fed holds steady
Macro is back in control ahead of this morning’s US GDP and inflation releases. After the Fed held rates steady at its latest meeting, MarketWatch said the data could shift expectations for the next policy move and reprice rate-sensitive equities. That puts long-duration areas, including growth software, in focus as traders map scenarios for a fast policy repricing.
Earnings reactions are adding crosscurrents. CNBC reported Alphabet’s results came in below expectations, with softness in Search-related revenue renewing debate over AI disruption and monetization. Separately, MarketWatch noted ServiceNow was indicated sharply lower premarket after its report as investors parsed outlook and billings signals. More context: Fed setup from yesterday’s premarket brief.
Most discussed
Eli Lilly lifts outlook again as GLP-1 demand stays strong
Eli Lilly ($LLY) led discussion after reporting quarterly results above expectations and raising its sales outlook again. CNBC said the company pointed to continued strength in demand for Zepbound and Mounjaro, keeping obesity and diabetes therapies central to growth expectations across the sector. MarketWatch also highlighted the higher sales outlook, reinforcing the market’s focus on how durable that demand profile remains.
With another outlook lift on the tape, attention often shifts from the quarter to what it implies for the broader group. Traders may watch how quickly expectations reprice across obesity and diabetes therapy names as sentiment adjusts to updated growth assumptions. The reaction can depend on how investors interpret follow-through commentary from management rather than the headline numbers alone.
Subscribe to continue reading your article
Free Forever. Enter your email to unlock the full brief and get it every trading morning before the open.
The Pre-Market Brief is generated with AI from published news reports and market data and may contain errors or delays. It is for information only and is not investment, legal or tax advice, or a recommendation or offer to buy or sell any security. Examples are hypothetical. ZORO does not provide personalized advice. You choose the rules you run and are responsible for the trades in your account, and your funds stay with your broker. Automated trading adds risks such as connectivity failures, latency and partial fills, and does not remove market risk. Past performance is not indicative of future results, and trading involves risk of loss. ZORO, its team and traders on the platform may hold positions in securities mentioned.